Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer

被引:0
作者
Haojun Shi
Yiusing Tsang
Yisi Yang
机构
[1] Ruijin Hospital,Department of General Surgery
[2] Shanghai Jiao Tong University School of Medicine,Graduate School of Asia
[3] Shanghai Institute for Endocrine and Metabolic Diseases,Pacific Studies
[4] Ruijin Hospital,undefined
[5] Shanghai Jiao Tong University School of Medicine,undefined
[6] Waseda University,undefined
来源
BMC Cancer | / 22卷
关键词
Pancreatic cancer; Cancer stemness; CEACAM5; Immune checkpoint; Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 421 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2019)Optimizing the outcomes of pancreatic cancer surgery Nat Rev Clin Oncol 16 11-26
[3]  
Siegel RL(2021)Pancreatic cancer: a review JAMA 326 851-862
[4]  
Laversanne M(2021)Immune checkpoint inhibitors in melanoma Lancet 398 1002-1014
[5]  
Soerjomataram I(2021)Toward personalized treatment approaches for non-small-cell lung cancer Nat Med 27 1345-1356
[6]  
Jemal A(2010)Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J Immunother 33 828-833
[7]  
Bray F(2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2455-2465
[8]  
Strobel O(2020)BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial Nat Med 26 878-885
[9]  
Neoptolemos J(2021)CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Lancet Oncol 22 118-131
[10]  
Jager D(2017)Hypermutation in pancreatic cancer Gastroenterology 152 68-74.e62